Navigation Links
Shire Supports Rare Disease Day 2010
Date:3/1/2010

CAMBRIDGE, Massachusetts and BASINGSTOKE, England, March 1, 2010 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced it will actively support Rare Disease Day across the world by generating media coverage in many countries to raise awareness and understanding of rare diseases.

Rare Disease Day seeks to call attention to rare diseases as a public health issue, and to reinforce the increased need for access to information, research and treatment. It is coordinated at the international level by European Organisation for Rare Diseases (EURORDIS) and by the National Organization for Rare Disorders (NORD) in the US.

It is estimated that there are between 5,000 and 8,000 known rare diseases affecting 250 million people in the world. Shire has commercially approved and available treatments for Fabry disease, Hereditary Angioedema (HAE) and Hunter syndrome. In addition, Shire expects the U.S. Food & Drug Administration (FDA) to issue its decision for VPRIVTM (velaglucerase alfa for injection), Shire's investigational enzyme replacement treatment for Type 1 Gaucher disease, by February 28.

"For many patients and their families, the journey to a diagnosis and subsequent treatment can be a long, complicated process," said Sylvie Gregoire, President of Shire Human Genetic Therapies (HGT). "Shire is committed to enabling people with life-altering conditions to lead better lives - and for us, this includes improving access to information as well as providing much-needed treatment for rare diseases."

    Shire's Global Rare Disease Day Initiatives include:

    - Extending BraveCommunity.com (http://www.bravecommunity.com), its
    online resource center that aims to connect patients with each other and
    to provide important information about rare diseases.

    - Supporting the Global Genes Project (http://www.globalgenesproject.org)
    , a grassroots effort to use denim jeans to raise global awareness of
    rare genetic disorders.

    - Supporting its non-profit partners as they visit Capitol Hill to
    advocate for patients with rare diseases in Washington, D.C.,

    - Co-sponsoring with FEDER (Spanish Federation for Rare Diseases) the
    Annual Running Race for Rare Disease Day in Madrid, Spain.

    - Organizing a special walk on February 28th in Brazil to raise awareness
    of rare diseases in the country. It is expected that more than 20 patient
    organizations and their members will participate.


    For the full press release please visit http://www.bravecommunity.com
    Media Contact
    Jessica Mann (Rest of the World) +44(0)1256-894-280

    Jessica Cotrone (North America, HGT) +1-617-613-4640
    http://www.shire.com

SOURCE Shire Pharmaceutical

Back to top
'/>"/>
SOURCE Shire Pharmaceutical
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Shire plc: Board Changes
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
10. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
11. Shire Engages Palio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... ... for their exceptionally efficient human mesenchymal stem/stromal cell (hMSC) expansion medium. ... media products engineered to radically streamline culture processes, minimize processing time, significantly ...
(Date:12/8/2016)... 2016  HedgePath Pharmaceuticals, Inc. (OTCQX: HPPI), a ... plans to commercialize innovative therapeutics for patients with ... were approved for trading on the OTCQX U.S. ... OTCQX, effective today, under the ticker symbol "HPPI." ... companies must meet high financial standards, follow best ...
(Date:12/7/2016)... ... 07, 2016 , ... ACEA Biosciences, Inc. presented today updated ... trial for its lead drug candidate, AC0010, at the World Conference on Lung ... determine the safety, antitumor activity, and recommended phase II dosage of AC0010 in ...
(Date:12/7/2016)... 7, 2016 /PRNewswire/ - Zenith Capital Corp. ("Zenith" or the "Company") ... presented at the Company,s Annual and Special Meeting. ... take place on Thursday, December 15, 2016 at ... (Room EC1040), 4825 Mount Royal Gate SW, Calgary, ... of meeting and management information circular, containing the matters to ...
Breaking Biology Technology:
(Date:12/2/2016)... , December 1, 2016 ... (Fingerprint, Voice), Future Technology (Iris Recognition System), Vehicle ... - Global Forecast to 2021", published by MarketsandMarkets, ... Million in 2016, and is projected to grow ... CAGR of 14.06%.      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
(Date:11/30/2016)... 2016 Not many of us realize that we spend ? of our ... need to do it well. Inadequate sleep levels have been found to lead to ... and even cancer. Maybe now is the best time to rethink how ... to manage their sleep quality? Continue Reading ... ...
(Date:11/29/2016)... BioDirection, a privately held medical device company ... detection of concussion and other traumatic brain injury (TBI), ... meeting with the U.S. Food and Drug Administration (FDA) ... During the meeting company representatives reviewed plans for clinical ... commencement of a planned pilot trial. ...
Breaking Biology News(10 mins):